A multicenter, registry-based cohort study showed no short-term benefit of the common practice of switching anticoagulants ...

Adoption of DOAC population management tool dashboard before July 2018 linked to decline in off-label dosing prescriptions HealthDay News — Early adoption of the direct oral anticoagulant (DOAC) ...

The risk for death goes up for patients with atrial fibrillation (AF) who are put on direct oral anticoagulants (DOAC) at dosages other than those approved for stroke prevention, whether higher or ...

The PROACT Xa trial has been halted prematurely after it was found that apixaban (Eliquis; Bristol Myers Squibb) carried a greater risk of blood clots leading to stroke when compared with warfarin in ...

The DOAC Dipstick (DOASENSE GmbH) is a single-use, point-of-care dipstick test that is used to detect direct oral anticoagulants (DOACs) in urine. The urine dipstick test detects DOACs (both factor Xa ...

Among patients hospitalized for atrial fibrillation (AF) or flutter, prescription of an off-label dose of a direct oral anticoagulant (DOAC) at discharge remains relatively common, according to data ...

Despite concerns about the potential bleeding risk, IV thrombolysis could be safely given to ischemic stroke patients within a day of direct oral anticoagulant (DOAC) therapy, according to ...

Credit: Getty Images. This registry-based cohort study aimed to assess both the frequency of prescription of concomitant aspirin (ASA) and DOAC therapy as well as its effect on clinical outcomes in ...

Study authors assessed the effectiveness and safety of DOACs compared with warfarin in patients with valvular atrial fibrillation. People with valvular atrial fibrillation (AF) who are new users of ...

Swedish cohort study shows 13% (95% CI, 2-22%) lower risk of kidney function decline or kidney failure and 12% (95% CI, 3-20%) lower risk of acute kidney injury with use of direct oral anticoagulants ...

Direct oral anticoagulants were associated with lower risks of ischemic stroke or systemic embolism and bleeding compared with warfarin. The study included patients with atrial fibrillation (AF) and ...

FREMONT, Calif., March 22, 2026 (GLOBE NEWSWIRE)-- CoaguSense, Inc., a leading developer of point-of-care coagulation monitoring systems and a subsidiary of i-SENS, Inc. (KOSDAQ: 099190), today ...